A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
Public ClinicalTrials.gov record NCT02017717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the safety and tolerability of nivolumab administered alone or in combination with ipilimumab in patients with different lines of GBM therapy.
Study identification
- NCT ID
- NCT02017717
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 529 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 7, 2014 (Actual)
- Primary completion
- Jun 17, 2019 (Actual)
- Completion
- Jun 21, 2024 (Actual)
- Last update posted
- Apr 4, 2025
2014 – 2024
United States locations
- U.S. sites
- 46
- U.S. states
- 20
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-3410 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| Local Institution - 0055 | Los Angeles | California | 90048 | — |
| Local Institution - 0009 | Los Angeles | California | 90095-1769 | — |
| UCLA Neuro-Oncology Program | Los Angeles | California | 90095-1769 | — |
| Local Institution - 0014 | San Francisco | California | 94143-0372 | — |
| The Regents of the University of California, San Francisco | San Francisco | California | 94143-0372 | — |
| Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| Local Institution - 0021 | Aurora | Colorado | 80045 | — |
| Local Institution - 0001 | New Haven | Connecticut | 06520 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06520 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Local Institution - 0002 | Atlanta | Georgia | 30322 | — |
| Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Johns Hopkins University School Of Medicine | Baltimore | Maryland | 21287 | — |
| Local Institution - 0008 | Baltimore | Maryland | 21287 | — |
| Beth Israel Deaconess Med Ctr | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Local Institution - 0006 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0043 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0056 | Boston | Massachusetts | 02215 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02215 | — |
| Henry Ford Health System | Detroit | Michigan | 48202-2608 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Local Institution - 0003 | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0007 | Durham | North Carolina | 27710 | — |
| Preston Robert Tisch Brain Tumor Center at Duke University | Durham | North Carolina | 27710 | — |
| Local Institution - 0049 | Cleveland | Ohio | 44106 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Thomas Jefferson University - Clinical Research Institute | Philadelphia | Pennsylvania | 19107 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Local Institution - 0023 | Charleston | South Carolina | 29425 | — |
| Medical University Of South Carolina | Charleston | South Carolina | 29425 | — |
| Local Institution - 0005 | Nashville | Tennessee | 37232 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Local Institution - 0024 | Houston | Texas | 77030-4009 | — |
| University Of Texas Md Anderson Cancer Ctr | Houston | Texas | 77030-4009 | — |
| University Of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| University of Washington - Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Local Institution - 0020 | Seattle | Washington | 98122 | — |
| Swedish Neuroscience Institute | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02017717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02017717 live on ClinicalTrials.gov.